

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>A61K 38/19</b>		A1	(11) International Publication Number: <b>WO 00/45836</b> (43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: <b>PCT/US00/02751</b> (22) International Filing Date: 2 February 2000 (02.02.00)  (30) Priority Data: 60/118,531 2 February 1999 (02.02.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant: RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street, Carson City, NV 89703 (US). (72) Inventor: AGGARWAL, Bharat, B.; 3920 Oberlin, Houston, TX 77005 (US). (74) Agent: WEILER, James, F.; Suite 1560, 1 Riverway, Houston, TX 77056 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> USES OF THANK, A TNF HOMOLOGUE THAT ACTIVATES APOPTOSIS <b>(57) Abstract</b> The present invention is directed to the applications of a novel cytokine, named THANK, for TNF homologue that activates apoptosis, NF- $\kappa$ B and c-jun N-terminal kinase. Such applications include using THANK inhibitors to inhibit the activation of NF- $\kappa$ B and to treat a pathological condition caused by the activation of NF- $\kappa$ B. Also provided is a method of inhibiting growth of a wide variety of tumor cells by administering THANK protein.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## USES OF THANK, A TNF HOMOLOGUE THAT ACTIVATES APOPTOSIS

5

10

### BACKGROUND OF THE INVENTION

#### Field of the Invention

The present invention relates generally to the fields of biochemistry and molecular oncology. More specifically, the present invention relates to uses of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear Factor- $\kappa$ B, and c-jun N-terminal kinase.

#### Description of the Related Art

In 1984, two homologous cytokines were reported to inhibit the growth of tumor cells specifically (1-7) and was named TNF- $\alpha$  and TNF- $\beta$  (also called lymphotoxin). Since then over 15 members of this family have been identified, including FasL, CD29L, CD30L, CD40L, OX-40L, 4-1BBL, LT- $\beta$ , TWEAK, TRAIL, RANKL/TRANCE, LIGHT, VEGI, and APRIL (8-16). At the amino acid sequence level, various members of the TNF family are 20-25% homologous to each other. Most members of this family play an important role in gene activation, proliferation, differentiation, and apoptosis. These ligands interact with the corresponding receptor, also members of the TNF receptor family, and

activate the transcription factors NF- $\kappa$ B and AP1 (9, 17), a stress-activated protein kinase (c-jun N-terminal protein kinase, JNK), and a cascade of caspases.

The prior art is deficient in the lack of uses of a novel member of the TNF family, named THANK, for TNF homologue that activates apoptosis, NF- $\kappa$ B, and JNK. For example, the prior art is deficient in the lack of applications of THANK in inhibiting tumor growth and applications of THANK inhibitors in inhibiting the activation of NF- $\kappa$ B. The present invention fulfills this long-standing need and desire in the art.

### SUMMARY OF THE INVENTION

15 By searching an expressed sequence tag (EST) data base using the amino acid sequence motif of TNF, a novel member of the TNF family, named THANK, was identified for TNF homologue that activates apoptosis, NF- $\kappa$ B, and JNK. THANK was primarily expressed by hematopoietic cells. The recombinant THANK activated NF- $\kappa$ B, c-jun 20 N-terminal kinase, caspase-3 and displayed anti-proliferative effects in U937 cells through binding sites distinct from those for TNF.

25 The present invention is directed to the applications of THANK, including using THANK inhibitors to inhibit the activation of NF- $\kappa$ B and to treat a pathological condition caused by the activation of NF- $\kappa$ B. Also provided is a method of inhibiting growth of a wide variety of tumor cells by administering THANK protein.

In one embodiment of the present invention, there is provided a method of inhibiting the activation of NF- $\kappa$ B in cells by treating the cells with a THANK inhibitor.

In another embodiment of the present invention, there is provided a method of treating a pathological condition caused by the activation of NF- $\kappa$ B in an individual by administering a THANK inhibitor in a therapeutically effective amount. Preferably, the pathological condition is selected from the group consisting of toxic shock, septic shock, acute phase response, viral infection, radiation susceptibility, atherosclerosis, cancer, acute inflammatory conditions, arthritis, allergy, and graft vs. host reaction.

In still another embodiment of the present invention, there is provided a method of inhibiting growth of tumor cells by administering a therapeutically effective amount of THANK protein. Preferably, the cells are selected from the group consisting of myeloid cells, colon cancer cells, prostate cancer cells, breast carcinoma cells, cervical carcinoma cells, chronic myeloid leukemic cells and acute myeloid leukemic cells. Still preferably, THANK protein is administered in a dose of from about 0.01 mg/kg of patient weight per day to about 100 mg/kg of patient weight per day.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may

be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

5 **Figure 1** shows the full length amino acid sequence of THANK (SEQ ID No. 1).

10 **Figure 2A** shows the amino acid sequence of THANK intracellular domain (SEQ ID No. 2), transmembrane domain (SEQ ID No. 3), extracellular domain (aa 78-111, SEQ ID No. 4) and the comparison of THANK extracellular domain (aa 112-285, SEQ ID No. 5) with mature form of TNF, LT, FasL and LIGHT (SEQ ID Nos. 6-9). Shaded areas indicate homology with LT, TNF, FasL and LIGHT. **Figure 2B** shows SDS-PAGE analysis of THANK (fraction B). **Figure 2C** shows western blot analysis of THANK (fraction B). **Figure 2D** shows tissue distribution of THANK mRNA. **Figure 2E** shows the expression of THANK mRNA by various cell lines. PBL, peripheral blood leucocytes.

15 **Figure 3A** shows the dose response of THANK-induced NF- $\kappa$ B activation. U937 cells ( $2 \times 10^6$ /ml) were treated with different concentrations of THANK for 60 min at 37°C and then assayed for NF- $\kappa$ B by EMSA. **Figure 3B** shows kinetics of NF- $\kappa$ B activation. U937 cells (2  $\times 10^6$ /ml) were treated with 1 nM of THANK for various lengths of time. **Figure 3C** shows supershift and specificity of NF- $\kappa$ B. Nuclear extract of THANK treated cells (lane 4) were incubated at room temperature for 60 min with anti-p50 (lane 5), anti-p65 (lane 6), anti-mixture of anti-p50 and anti-p65 (lane 7), anti-c-Rel (lane 8), anti-cyclin D1 (lane 9), preimmune serum (lane 10), unlabeled NF- $\kappa$ B oligo nucleotide (lane 2) and then assayed for NF- $\kappa$ B. Lane 1 shows results for free probe, and lanes 3 and 4 show the THANK-untreated and

treated cells, respectively. **Figure 3D** shows effect of anti-TANK polyclonal antibodies on THANK-induced NF- $\kappa$ B activation in U937 cells. THANK was preincubated with anti-TANK antibodies at a dilution of 1:100 or 1:1000 before cells were exposed. **Figure 3E** shows effect of trypsinization and heat denaturation on the ability of THANK to activate NF- $\kappa$ B in U937 cells. THANK was treated with 0.25% trypsin at 37°C for 60 min and then checked for its ability to activate NF- $\kappa$ B (lane 3). The effect of trypsin alone is shown in lane 4. THANK was boiled at 100°C for 10 min, and used for the activation of NF- $\kappa$ B (lane 5). Lane 1 and lane 2 represent NF- $\kappa$ B activation for untreated and THANK treated U937 cells, respectively.

**Figure 4A** shows the dose response of THANK-induced JNK activation. U937 cells ( $2 \times 10^6$  /ml) were treated with different concentrations of THANK for 1 h at 37°C and assayed for JNK activation as described in the methods. Lower panel shows equal loading of protein. **Figure 4B** shows kinetics of THANK-induced activation of JNK. U937 cells ( $2 \times 10^6$  /ml) were treated with 1 nM THANK for indicated time period and assayed for JNK activation. Lower panel shows equal loading of protein.

**Figure 5A** shows the dose-dependent cytotoxic effects of THANK against U937 cells.  $5 \times 10^3$  cells/well were incubated in triplicate with various concentrations of THANK and then examined for cell viability after 72 hours. Untreated control is expressed as 100%. **Figure 5B** shows THANK-induced cleavage of PARP in U937 cells. U937 cells ( $2 \times 10^6$  cells/ml) were treated with 0.1, 1 and 10 nM THANK in presence of cycloheximide (10  $\mu$ g/ml) for 2 hours at 37°C. In order to compare the cleavage, TNF was used as a positive control. **Figure 5C** shows competitive inhibition of labeled TNF binding to U937 cells by unlabeled TNF (20 nM) and THANK (150 nM). U937 cells

( $0.5 \times 10^6$  cells/well) were incubated with  $0.25 \times 10^6$  cpm of  $^{125}\text{I}$ -TNF in ice bath for 1 hour in presence or absence of the unlabeled competitors. Cell-bound radioactivity was measured in a gamma counter. Results are expressed as mean  $\pm$  S.D.

5

### DETAILED DESCRIPTION OF THE INVENTION

Using the amino acid sequence motif of TNF, an EST database was searched. A novel full-length cDNA encoding 285 amino acid residues (SEQ ID No. 1, Figure 1) was identified, and named THANK. THANK is a type II transmembrane protein with 15-20% overall amino acid sequence homology to TNF, LT- $\alpha$ , FasL and LIGHT, all members of the TNF family. The mRNA for THANK was expressed at high levels by peripheral blood leukocytes, lymph node, spleen, and thymus and at low levels by small intestine, pancreas, placenta, and lungs. THANK was also prominently expressed in hematopoietic cell lines. The recombinant purified protein expressed in the baculovirus system had an approximate molecular size 20 kDa with amino terminal sequence of LK1FEP (SEQ ID No. 10). Treatment of human myeloid U-937 cells with purified THANK activated NF- $\kappa$ B consisting of p50 and p65. Activation was time- and dose-dependent, beginning with as little as 1 pM of the cytokines and as early as 15 min. Under the same conditions, THANK also activated c-jun N-terminal kinase (JNK) in U937 cells. THANK also strongly suppressed the growth of tumor cell lines and activated caspase-3. Although THANK had all the activities and potency of TNF, it did not bind to the TNF receptors, which indicates that THANK is a novel cytokine that belongs to the TNF family and activates apoptosis, NF- $\kappa$ B, and JNK through a distinct receptor.

The present invention is directed to various applications of THANK, including using THANK inhibitors to inhibit the activation of NF- $\kappa$ B and to treat a pathological condition caused by the activation of NF- $\kappa$ B. Also provided is a method of inhibiting growth of a wide variety of tumor cells by administering THANK protein.

5 In one embodiment of the present invention, there is provided a method of inhibiting the activation of NF- $\kappa$ B in cells by treating the cells with a THANK inhibitor.

10 In another embodiment of the present invention, there is provided a method of treating a pathological condition caused by the activation of NF- $\kappa$ B in an individual by administering a THANK inhibitor in a therapeutically effective amount. Preferably, the pathological condition is selected from the group consisting of toxic shock, septic shock, acute phase response, viral infection, radiation susceptibility, 15 atherosclerosis, cancer, acute inflammatory conditions, arthritis, allergy, and graft vs. host reaction.

20 In still another embodiment of the present invention, there is provided a method of inhibiting growth of tumor cells by administering a therapeutically effective amount of the THANK protein. Preferably, the THANK protein is used to treat tumor cells such as myeloid cells, colon cancer cells, prostate cancer cells, breast carcinoma cells, cervical carcinoma cells, chronic myeloid leukemic cells and acute myeloid leukemic cells. Generally, the THANK protein may be administered in any pharmacological dose which inhibits or kills 25 tumors. Preferably, the THANK protein is administered in a dose of from about 0.01 mg/kg of patient weight per day to about 100 mg/kg of patient weight per day.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

5

### EXAMPLE 1

#### Identification, Cloning, Expression, and Purification of THANK

Using high throughput automated DNA sequence analysis of randomly selected human cDNA clones, a database containing more than two million ESTs obtained from over 750 different cDNA libraries was generated by Human Genome Sciences, Inc. A specific homology and motif search using the known amino acid sequence motif of TNF family members against this database revealed several ESTs having homology to members of the TNF family. One full length cDNA clone (HNEDU15) encoding an intact N-terminal signal peptide was isolated from a human neutrophil library and selected for further investigation. The complete cDNA sequence of both strands of this clone was determined, and its homology to TNF was confirmed. This gene product was named THANK.

THANK is a 285 amino acid long type II transmembrane protein (SEQ ID No. 1, Figure 1). The intracellular domain was found to be located between amino acid residues 1 through 46 (SEQ ID No. 2), and the transmembrane domain between amino acid residues 47 through 77 (SEQ ID No. 3) (Figure 2A).

The cDNA encoding the extracellular domain of THANK (aa 78-111, SEQ ID No. 4 and 112-285, SEQ ID No. 5) was amplified employing the PCR technique using the following primers: 5' *Bam*HI, GCGGGATCCCAGCCTCCGGGCAGAGC (SEQ ID No. 11) and 3' *Xba*I,

5 GCGTCTAGATCACAGCACTTCAATGC (SEQ ID No. 12). The amplified fragment was purified, digested with *Bam*HI and *Xba*I, and cloned into a baculovirus expression vector pA2-GP, derived from pVL94. The cloning, expression and confirmation of the identity of the cloned product were performed using standard techniques (18).

10 Recombinant THANK was purified from the clarified culture supernatant of 92 h post-infected Sf9 cells. The protein was stepwise purified by cation and anion exchange chromatography. The purified THANK was analyzed for purity by 12% SDS-PAGE and by western blot analysis.

## EXAMPLE 2

15 Northern Blot Analysis

Two multiple human tissue northern blots containing 2  $\mu$ g of poly (A)<sup>+</sup> RNA per lane of various tissues (Clontech, Palo Alto, CA) were probed with <sup>32</sup>P-labeled THANK cDNA. RNA from a selected panel of human cell lines were probed following the same technique.

20

## EXAMPLE 3

Production of THANK Antibodies

25 Antibodies against THANK were raised by injecting 0.2 mg purified recombinant antigen in Freund's complete adjuvant (Difco Laboratories) subcutaneously into a rabbit. After three weeks, the injection was repeated and the rabbit was bled every third week. The specificity of the antiserum was tested by ELISA and western blot.

**EXAMPLE 4**Receptor-Binding Assay

TNF receptor-binding assay was performed following a modified procedure previously described (19). Briefly,  $0.5 \times 10^6$  cells/well (triplicate well) in 100  $\mu$ l binding medium (RPMI-1640 containing 10% FBS) were incubated with  $^{125}\text{I}$ -labelled TNF ( $2.5 \times 10^5$  cpm/well, specific activity 40 mCi/mg) either alone (total binding) or in the presence of 20 nM unlabeled TNF (nonspecific binding) or 150 nM unlabeled THANK in an ice bath for 1 h. Thereafter, cells were washed three times with ice-cold PBS containing 0.1% BSA to remove unbound  $^{125}\text{I}$ -TNF. The cells were dried at 80°C, and the cell bound radioactivity was determined in a gamma counter (Cobra-Auto Gamma, Packard Instrument Co.)

15

**EXAMPLE 5**Electrophoretic Mobility Shift Assay (EMSA)

NF- $\kappa$ B activation was analyzed by EMSA as described previously (20, 21). In brief, 6  $\mu$ g nuclear extracts prepared from THANK-treated cells were incubated with  $^{32}\text{P}$ -end-labeled 45-mer double-stranded NF- $\kappa$ B oligonucleotide for 15 min at 37 °C, and the DNA-protein complex resolved in 7.5% native polyacrylamide gel. The specificity of binding was examined by competition with unlabeled 100-fold excess oligonucleotide. The specificity of binding was also determined by supershift of the DNA-protein complex using specific and irrelevant antibodies. The samples of supershift experiments were resolved on 5.5% native gels. The radioactive bands from dried gels

were visualized and quantitated by PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using ImageQuant software.

5

### EXAMPLE 6

#### Western Blot of THANK

Purified THANK sample was resolved on 12% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and probed with 10 polyclonal antibodies (1:6000) raised in rabbits. The blot was then treated with HRP-conjugated secondary antibodies and finally detected by chemiluminescence (ECL, Amersham Pharmacia Biotech. Arlington Heights, IL).

15

### EXAMPLE 7

#### c-Jun Kinase Assay

The c-Jun kinase assay was performed by a modified 20 method as described earlier (22). Briefly, 100- $\mu$ g cytoplasmic extracts were treated with anti-JNK1 antibodies, the immunocomplexes were precipitated with protein A/G-Sepharose beads (Pierce, Rockford, IL) and assayed for the enzymatic activity by using glutathione S-transferase-Jun (aa 1-79) as substrate (2  $\mu$ g) in the presence of 10  $\mu$ Ci  $[^{32}P]$ ATP. The kinase reaction was carried out by incubating the above 25 mixture at 30°C in kinase assay buffer for 15 minutes. The reaction was stopped by adding SDS sample buffer, followed by boiling. Finally, protein was resolved on a 9% acrylamide gel under reduced conditions.

The radioactive bands of the dried gel were visualized and quantitated by phosphorImager as mentioned previously.

To determine the total amount of JNK1 protein, 30 µg of the cytoplasmic extracts were loaded on 9% acrylamide gels. After 5 electrophoresis, the protein was transferred to nitrocellulose membranes, blocked with 5% non-fat milk protein and probed with rabbit polyclonal antibodies (1:3000) against JNK1. The blots were then reacted with HRP-conjugated secondary antibodies and finally detected by chemiluminescence (ECL, Amersham)

10

#### EXAMPLE 8

##### Cytotoxicity Assays

15 The cytotoxic effects of THANK against tumor cells were measured by modified tetrazolium salt (MTT) assay described earlier (23) and by its ability to activate caspase-3 leading to cleavage of poly (ADP-ribose) polymerase (PARP) (24). For cytotoxicity,  $5 \times 10^3$  cells in 0.1 ml were plated in triplicate in 96-well plates and exposed to 20 variable concentrations of either THANK or TNF (for comparison) in 0.1 ml. After 72 h incubation at 37°C, cells were examined for viability. To estimate caspase-3 activation by PARP cleavage, cell extracts (50 µg/sample) were resolved on 7.5% acrylamide gels, electrophoresed, transferred to nitrocellulose membranes, blocked 25 with 5% non-fat milk protein, probed with PARP monoclonal antibody (1:3000) and detected by ECL as indicated above.

**EXAMPLE 9**Identification, Sequence, and Purification of THANK

The predicted amino acid sequence of mature THANK (112-285, SEQ ID No. 5) is 15%, 16%, 18% and 19% identical to LIGHT, FasL, TNF and LT- $\alpha$ , respectively (Figure 2A). The cDNA for this novel cytokine was cloned and expressed in a baculovirus expression system. In CM cellulose cation-exchange chromatography, THANK eluted first with 1 M NaCl (fraction A) and then with 1.5 M NaCl (fraction B). Fractions A and B had approximate molecular mass of 23 kDa and 20 kDa, respectively on 12% SDS-PAGE (Figure 2B); and amino terminal sequences of LKIFEP (SEQ ID No. 10) and AVQGP (SEQ ID No. 13) starting at AA112 and AA134, respectively. An apparently higher molecular size obtained by SDS-PAGE than that predicted from the number of amino acids suggested a post-translational modification. The amino acid sequence of the mature THANK lacked, however, the potential N-glycosylation site. Polyclonal antibodies prepared against THANK recognized the cytokine on western blot (Figure 2C).

20

**EXAMPLE 10**Tissue and Cell Line Distribution of THANK

Northern blot analysis indicated that THANK was expressed in peripheral blood leukocytes (PBL), spleen, thymus, lung, placenta, small intestine and pancreas; with highest expression in PBL (Figure 2D). Analysis of the cell line blot (Clonetech Inc.) revealed very high expression in HL60, detectable expression in K562, A549, and G361, and no detectable transcript in HeLa, MOLT4, Raji, and SW480 cell

lines. Thus cells and tissues of the immune system expressed THANK transcripts.

5

### EXAMPLE 11

#### THANK Activates NF-κB

One of the earliest events activated by most members of the TNF superfamily is NF-κB activation (25). The results depicted in Figures 3A & 3B indicate that THANK activated NF-κB in a dose and time-dependent manner. Less than 10 pM THANK was enough to activate NF-κB in U937 cells, though peak activation was obtained at 1 nM (Figure 3A). THANK induced optimum NF-κB activation within 60 min at 1 nM; no significant increase was thereafter (Figure 3B). The gel shift band was specific, as its formation could be eliminated with excess unlabeled oligonucleotide. It was supershifted by anti-p50 and anti-p65 antibodies only (Figure 3C), thus indicating that the nuclear factor was composed of p50 and p65 subunits. No significant difference was found in the ability to activate NF-κB between 20 and 23 kDa forms of THANK indicating that residues 112 through 134 are optional for the biological activity (data not shown).

To ascertain that the observed activation was due to THANK and not a contaminant, the protein was preincubated with anti-TANK polyclonal antibodies before treatment with the cells. Figure 3D shows a lack of NF-κB activation after treatment of THANK with antibodies even at a 1 to 1000 dilution. Antibody against THANK by itself had no effect. To further ascertain that NF-κB activation was due to the proteinaceous nature of THANK, the protein was either digested with trypsin or heat-denatured prior to treatment. Both treatments

completely abolished NF- $\kappa$ B activation in U937 cells, confirming that THANK was responsible for this activation (Figure 3E). Although THANK was as potent as TNF with respect to both dose and time required for NF- $\kappa$ B activation, the overall amplitude of response was 5 less with THANK. In this respect the activity of THANK was comparable with LT- $\alpha$  (21).

#### EXAMPLE 12

10

##### THANK Activates c-Jun N-terminal Kinase

The activation of c-Jun kinase (JNK) is another early event that is initiated by different members of the TNF family (17, 22). THANK activated JNK activity in a time- and dose-dependent manner 15 (Figures 4A & 4B). At 10 pM the activity increased by 2.5-fold; at 1 nM it reached 4.4 fold. An additional increase in THANK concentration slightly decreased activation (Figure 4A). The peak activation of JNK was observed at 60 min (3.3-fold increase), which gradually decreased thereafter (Figure 4B). These results suggest that, like TNF, THANK 20 transiently activates JNK in U937 cells. The activation of JNK by THANK was not due to an increase in JNK protein levels, as immunoblot analysis demonstrated comparable JNK1 expression at all dose and time points (Figures 4A & 4B, lower panels)

25

#### EXAMPLE 13

##### THANK-Induced Cytotoxicity and Caspase-3 Activation

Activations of NF- $\kappa$ B and JNK are early cellular responses to TNF, which are followed by cytotoxic effects to tumor cells. The effect

of different concentrations of THANK on the cytotoxic effects against tumor cell lines was examined and compared with that of TNF.

Results in Figure 5A show that THANK inhibited the growth of human histiocytic lymphoma U-937 cells in a dose-dependent manner. Besides U-937 cells, THANK also inhibited the growth of prostate cancer (PC-3) cells, colon cancer cells (HT-29), cervical carcinoma cells (HeLa), breast carcinoma cells (MCF-7), and embryonic kidney cells (A293) (data not shown). The growth inhibition curve of THANK was superimposable with that of TNF, indicating comparable potency.

Degradation of PARP by caspase-3 is one of the hallmarks of apoptosis in tumor cells (26). It was found that treatment of U-937 cells with THANK for 2 h induced partial cleavage of PARP in U937 cells, whereas TNF almost completely cleaved PARP under these conditions (Figure 5B). This suggests that THANK can activate caspase-3, though not so strongly as TNF.

#### EXAMPLE 14

THANK Binds to Receptors Distinct from TNF Receptors

It was previously shown that TNF and LT, which share homology with each other to the same extent as THANK, bind to the same cell surface receptors (4). Since THANK has significant amino acid sequence homology with TNF, and like TNF exhibits cytotoxic effects, and activates NF- $\kappa$ B and JNK, its binding to the TNF receptor was examined. The receptor binding results (Figure 5C) show that 20 nM unlabeled TNF almost completely blocked the binding of  $^{125}$ I-labeled TNF to U-937 cells, whereas 150 nM unlabeled THANK did not compete

for  $^{125}\text{I}$ -TNF binding sites. These results suggest that THANK interacts with U937 cells through a receptor distinct from that for TNF.

In summary, a novel cytokine expressed by hematopoietic cells was identified, which can, like TNF and LT- $\alpha$ , activate NF- $\kappa$ B and

5 JNK and inhibit the growth of a wide variety of tumor cells. Although the structure of THANK also exhibits homology to FasL and LIGHT, the latter have not been reported to activate NF- $\kappa$ B. Preliminary results by using flow cytometry indicate that THANK protein is expressed by promyelomonocytic HL-60 cells (data not shown). Because THANK is  
10 expressed by hematopoietic cells, it appears to be similar to LT- $\alpha$  and dissimilar from other members of the TNF superfamily. Among all the members of the TNF superfamily, THANK exhibits cytotoxic effects similar to TNF and LT- $\alpha$ . Whether THANK exhibits immunomodulatory activities and *in vivo* antitumor activities is currently under  
15 investigation.

The following references were cited herewith.

1. Aggarwal, et al., 1984 *J Biol Chem*, 259:686-691.
2. Gray, et al., 1984 *Nature*, 312:721-724.
3. Pennica, et al., 1984 *Nature*, 312:724-729.
20. 4. Aggarwal, et al., 1985 *Nature*, 318:665-667.
5. Aggarwal, et al., 1985 *J Biol Chem*, 260:2334-2344.
6. Aggarwal, et al., *J Biol Chem*, 260:2345-2354.
7. Sugarman, et al., 1985 *Science*, 230:943-945.
8. Aggarwal, et al., 1996 *Eur. Cytokine Netw.* 7: 93-124.
25. 9. Smith, et al., 1994 *Cell* 76: 959-962.
10. Wiley, et al., 1995 *Immunity*, 8:21-30.
12. Hahne, et al., 1998. *J. Exp. Med.* 188:1185-90.
13. Chicheportiche, et al., *J. Biol. Chem.* 272 : 32401-32410.
14. Zhai, et al., *FASEB J.* (In press).

15. Anderson, et al., *Nature*. 390:175-9.
16. Wong, et al., *J. Biol. Chem.* 272: 25190-4.
17. Singh, et al., 1998 *J. Interferon and Cytokine Res.* 18, 439-450.
18. Ni, et al., 1997 *J. Biol. Chem.* 272 : 10853-10858.
- 5 19. Higuchi, et al., 1992 *Anal. Biochem.* 204 : 53-57.
20. Schreiber, et al., 1989 *Nucleic Acids Res.* 17 : 6419-6422.
21. Chaturvedi, et al., 1994 *J. Biol. Chem.* 269 : 14575-14583.
22. Kumar, et al., 1998. *Methods in Enzymology*, Vol. 000 (ed. L. Packer), Academic Press, pp. 339-345.
- 10 23. Hansen, et al., 1989 *J. Immunol. Methods*. 119: 203-210.
24. Haridas, et al., 1998 *J. Immunol.* 160, 3152-3162.
25. Baeuerle, et al., 1996 *Cell* 87:13-20.
26. Tewari, et al., 1995. *Cell* 81:801-9.

Any patents or publications mentioned in this specification  
15 are indicative of the levels of those skilled in the art to which the  
invention pertains. These patents and publications are herein  
incorporated by reference to the same extent as if each individual  
publication was specifically and individually indicated to be  
incorporated by reference.

20 One skilled in the art will readily appreciate that the  
present invention is well adapted to carry out the objects and obtain  
the ends and advantages mentioned, as well as those inherent therein.  
The present examples along with the methods, procedures, treatments,  
molecules, and specific compounds described herein are presently  
25 representative of preferred embodiments, are exemplary, and are not  
intended as limitations on the scope of the invention. Changes therein  
and other uses will occur to those skilled in the art which are  
encompassed within the spirit of the invention as defined by the scope  
of the claims.

**WHAT IS CLAIMED IS:**

1. A method of inhibiting the activation of nuclear  
5 factor- $\kappa$ B in cells, comprising the step of treating said cells with a  
THANK inhibitor.

10 2. A method for treating a pathological condition caused  
by the activation of nuclear factor- $\kappa$ B in an individual, comprising the  
step of administering to said individual a therapeutically effective  
amount of a THANK inhibitor.

15 3. The method of claim 2, wherein said pathological  
condition is selected from the group consisting of toxic shock, septic  
shock, acute phase response, viral infection, radiation susceptibility,  
atherosclerosis, cancer, acute inflammatory conditions, arthritis,  
allergy, and graft vs. host reaction.

20

4. A method of inhibiting growth of tumor cells,  
comprising the step of administering to said cells a therapeutically  
effective amount of THANK protein.

25

5. The method of claim 4, wherein said cells are selected  
from the group consisting of myeloid cells, colon cancer cells, prostate

cancer cells, breast carcinoma cells, cervical carcinoma cells, chronic myeloid leukemic cells and acute myeloid leukemic cells.

5

6. The method of claim 4, wherein said THANK protein is administered in a dose of from about 0.01 mg/kg of patient weight per day to about 100 mg/kg of patient weight per day.

## Amino Acid Sequence of THANK (SEQ ID No. 1)

Met Asp Asp Ser Thr Glu Arg Glu Gln Ser Arg Leu Thr Ser Cys  
Leu Lys Lys Arg Glu Glu Met Lys Leu Lys Glu Cys Val Ser Ile  
Leu Pro Arg Lys Glu Ser Pro Ser Val Arg Ser Ser Lys Asp Gly  
Lys Leu Leu Ala Ala Thr Leu Leu Leu Ala Leu Leu Ser Cys Cys  
Leu Thr Val Val Ser Phe Tyr Gln Val Ala Ala Leu Gln Gly Asp  
Leu Ala Ser Leu Arg Ala Glu Leu Gln Gly His His Ala Glu Lys  
Leu Pro Ala Gly Ala Gly Ala Pro Lys Ala Gly Leu Glu Glu Ala  
Pro Ala Val Thr Ala Gly Leu Lys Ile Phe Glu Pro Pro Ala Pro  
Gly Glu Gly Asn Ser Ser Gln Asn Ser Arg Asn Lys Arg Ala Val  
Gln Gly Pro Glu Glu Thr Val Thr Gln Asp Cys Leu Gln Leu Ile  
Ala Asp Ser Glu Thr Pro Thr Ile Gln Lys Gly Ser Tyr Thr Phe  
Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser Ala Leu Glu Glu  
Lys Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile  
Tyr Gly Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met Gly His  
Leu Ile Gln Arg Lys Lys Val His Val Phe Gly Asp Glu Leu Ser  
Leu Val Thr Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu  
Pro Asn Asn Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu  
Gly Asp Glu Leu Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile  
Ser Leu Asp Gly Asp Val Thr Phe Phe Gly Ala Leu Lys Leu Leu

FIG. 1

1 MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDKR		46 Intracellular	
47 LLATLILLLSCCLTVVSEYQVAALQDILA		77 Transmembrane domain	
78 SLRAELQGHAEKLPAAGAPKAGLEEAPAVTAG		112 to 285 Extracellular domain	
L	K I F E P P A P G	E G N S S Q N S R N K R A V Q G	THANK 112-285
E	P G V G L	T P S A A Q T A R Q H P K M H L	LT alpha 35-205
V	R S S S R	T P S - - - - -	TNF alpha 77-233
Q	I G H P S P P E	P P E K K E - - - - -	FasL 130-281
I	I Q E R R	S H E - - - - -	LIGHT 83-240
27	P E E T V T Q D C L Q L I	A D S E - - - - -	THANK 112-285
23	A H S T L K P A	A H L I - G D P S - - - - -	LT alpha 35-205
10	D K P V	A H V V - A N P Q - - - - -	TNF alpha 77-233
14	L R K V	A H L T G K S N S - - - - -	FasL 130-281
10	V N P A	A H L T G A N S S L T G S G P - - - - -	LIGHT 83-240
53	T F V P W L L S F K R G	S A L E E K E N K I L V K E T	THANK 112-285
43	- L L W R A N T D R A F L	- Q D G F E S L S N N S L V P T S	LT alpha 35-205
26	- L Q W L N R R A N A L L	- A N G V E E L R D N Q L V V P S E	TNF alpha 77-233
31	- L E W E D T Y G I V L	- S C G V K Y K K G G L V I N E T	FasL 130-281
30	- L L W E T Q	- R G L S Y H D G A L V V T K A	LIGHT 83-240

Intracellular domain:	SEQ ID NO:2
Transmembrane domain:	SEQ ID NO:3
Extracellular domain:	SEQ ID NO:4
78-111:	SEQ ID NO:5
112-285:	

FIG. 2A-1

80	G Y F F I Y G Q V L Y	T D K T Y - - -	A - - -	M G H L I O	THANK 112-285
71	G L Y F V Y S Q V V F	S G K A Y - - -	P K A T - - -	S S P L Y L	LT alpha 35-205
54	G L Y L I Y S Q V L F	G Q G C - - -	P - - -	S T H V L L	TNF alpha 77-233
58	G L Y F V Y S K V V Y	R G Q S C - - -	N - - -	N L P - - -	FasL 130-281
57	G Y Y I Y S K V Q L G	G V G C - - -	P L G L A S T - - -	I	LIGHT 83-240
103	R K K V H V F G D E L S L	V T L F R C I O N M - - -	P E -	THANK 112-285	
98	A H E V Q L F S S Q Y P F H V P L L S S Q K M V - - -	Y P -	LT alpha 35-205		
77	T H T I S R I A V S Y Q T K V N M S A I K S P C O R E T P	Y C -	TNF alpha 77-233		
79	S H K V Y M R N S K Y P Q D L V M M E G K M M S - - -	Y C -	FasL 130-281		
81	T H G L Y K R T P R Y P E E L L E L L V S Q Q S P C G R A T -	Y C -	LIGHT 83-240		
128	- - T L P N - - -	N S C Y S A G I A K L E E G D E L Q L A I	THANK 112-285		
124	- - G L Q E P W L H S M Y H G A A E Q L T Q G D Q L S - - T H	Y H G A A E Q L T Q G D Q L S - - T H	LT alpha 35-205		
107	E G A E A K P W Y E P I Y L G G V F Q L E K G D R L S - - A E	Y L G G V F Q L E K G D R L S - - A E	TNF alpha 77-233		
105	- - T T G Q M W A R S S Y L G A V V F N L T S A D H L Y - - V N	Y L G A V V F N L T S A D H L Y - - V N	FasL 130-281		
110	- - S S R V W W D S S F L G G V V H L E A G E E V V - - V R	Y L G A V V F N L T S A D H L Y - - V N	LIGHT 83-240		
153	P R E N A Q I S L D - G D V T F F G A L K L - L .	Y L E A G F A L	THANK 112-285		
151	T D G I P H L S - P S T V F F G A F A L	Y L E A G F A L	LT alpha 35-205		
136	I N R P D Y L D F A E S G Q V Y F G I I A L	Y L E A G F A L	TNF alpha 77-233		
132	V S E L S L V N F - E E S Q T F F G L Y K L	Y L E A G F A L	FasL 130-281		
137	V L D E R L V R L R D G T R S Y F G A F M V	Y L E A G F A L	LIGHT 83-240		

SEQ ID NO:5  
 SEQ ID NO:6  
 SEQ ID NO:7  
 SEQ ID NO:8  
 SEQ ID NO:9

THANK 112-285:  
 LT alpha 35-205:  
 TNF alpha 77-233:  
 FasL 130-281:  
 LIGHT 83-240:

kDa




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG.3A




FIG. 3B

1 2 3 4 5 6 7 8 9 10




FIG. 3C

1:100 1:100 + 1:1000 + 1:1000  
Anti-THANK  
THANK

FIG. 3D

FP 1 2 3 4 5



FIG. 3E




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 5C

## SEQUENCE LISTING

<110> Aggarwal, Bharat B.  
<120> Uses of THANK, a TNF homologue that Activates  
Apoptosis  
5 <130> D6206PCT  
<140>  
<141> 2000-02-02  
<150> US 60/118,531  
<151> 1999-02-02  
10 <160> 13  
  
<210> 1  
<211> 285  
<212> PRT  
15 <213> *Homo sapiens*  
<220>  
<223> amino acid sequence of THANK protein  
<400> 1  
  
20 Met Asp Asp Ser Thr Glu Arg Glu Gln Ser Arg Leu Thr Ser Cys  
5 10 15  
Leu Lys Lys Arg Glu Glu Met Lys Leu Lys Glu Cys Val Ser Ile  
20 25 30  
Leu Pro Arg Lys Glu Ser Pro Ser Val Arg Ser Ser Lys Asp Gly  
25 35 40 45  
Lys Leu Leu Ala Ala Thr Leu Leu Leu Ala Leu Leu Ser Cys Cys  
50 55 60  
Leu Thr Val Val Ser Phe Tyr Gln Val Ala Ala Leu Gln Gly Asp  
65 70 75  
30 Leu Ala Ser Leu Arg Ala Glu Leu Gln Gly His His Ala Glu Lys  
80 85 90  
Leu Pro Ala Gly Ala Gly Ala Pro Lys Ala Gly Leu Glu Glu Ala  
95 100 105  
Pro Ala Val Thr Ala Gly Leu Lys Ile Phe Glu Pro Pro Ala Pro  
35 110 115 120  
Gly Glu Gly Asn Ser Ser Gln Asn Ser Arg Asn Lys Arg Ala Val  
125 130 135

Gln Gly Pro Glu Glu Thr Val Thr Gln Asp Cys Leu Gln Leu Ile  
 140 145 150  
 Ala Asp Ser Glu Thr Pro Thr Ile Gln Lys Gly Ser Tyr Thr Phe  
 155 160 165  
 5 Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser Ala Leu Glu Glu  
 170 175 180  
 Lys Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile  
 185 190 195  
 Tyr Gly Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met Gly His  
 10 200 205 210  
 Leu Ile Gln Arg Lys Lys Val His Val Phe Gly Asp Glu Leu Ser  
 215 220 225  
 Leu Val Thr Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu  
 230 235 240  
 15 Pro Asn Asn Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu  
 245 250 255  
 Gly Asp Glu Leu Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile  
 260 265 270  
 Ser Leu Asp Gly Asp Val Thr Phe Phe Gly Ala Leu Lys Leu Leu  
 20 275 280 285  
  
 <210> 2  
 <211> 46  
 25 <212> PRT  
 <213> *Homo sapiens*  
 <220>  
 <221> domain  
 <222> 1..46  
 30 <223> sequence of THANK intracellular domain  
 <400> 2  
 Met Asp Asp Ser Thr Glu Arg Glu Gln Ser Arg Leu Thr Ser Cys  
 5 10 15  
 Leu Lys Lys Arg Glu Glu Met Lys Leu Lys Glu Cys Val Ser Ile  
 35 20 25 30  
 Leu Pro Arg Lys Glu Ser Pro Ser Val Arg Ser Ser Lys Asp Gly  
 35 40 45

Lys

5           <210>    3  
      <211>    31  
      <212>    PRT  
      <213>    *Homo sapiens*  
      <220>  
      <221>    domain  
10        <222>    47..77  
      <223>    sequence of THANK transmembrane domain  
      <400>    3  
Leu Leu Ala Ala Thr Leu Leu Leu Ala Leu Leu Ser Cys Cys Leu  
                  5                 10                 15  
15        Thr Val Val Ser Phe Tyr Gln Val Ala Ala Leu Gln Gly Asp Leu  
                  20                 25                 30  
Ala  
  
20        <210>    4  
      <211>    34  
      <212>    PRT  
      <213>    *Homo sapiens*  
      <220>  
      <221>    domain  
25        <222>    78..111  
      <223>    sequence of THANK extracellular domain  
      <400>    4  
Ser Leu Arg Ala Glu Leu Gln Gly His His Ala Glu Lys Leu Pro  
30        5                 10                 15  
Ala Gly Ala Gly Ala Pro Lys Ala Gly Leu Glu Glu Ala Pro Ala  
                 20                 25                 30  
Val Thr Ala Gly  
  
35  
      <210>    5  
      <211>    174

<212> PRT  
<213> *Homo sapiens*  
<220>  
<221> domain  
5 <222> 112..285  
<223> sequence of THANK extracellular domain  
<400> 5

Leu Lys Ile Phe Glu Pro Pro Ala Pro Gly Glu Gly Asn Ser Ser  
5 10 15

10 Gln Asn Ser Arg Asn Lys Arg Ala Val Gln Gly Pro Glu Glu Thr  
20 25 30

Val Thr Gln Asp Cys Leu Gln Leu Ile Ala Asp Ser Glu Thr Pro  
35 40 45

Thr Ile Gln Lys Gly Ser Tyr Thr Phe Val Pro Trp Leu Leu Ser  
50 55 60

Phe Lys Arg Gly Ser Ala Leu Glu Glu Lys Glu Asn Lys Ile Leu  
65 70 75

Val Lys Glu Thr Gly Tyr Phe Phe Ile Tyr Gly Gln Val Leu Tyr  
80 85 90

20 Thr Asp Lys Thr Tyr Ala Met Gly His Leu Ile Gln Arg Lys Lys  
95 100 105

Val His Val Phe Gly Asp Glu Leu Ser Leu Val Thr Leu Phe Arg  
110 115 120

Cys Ile Gln Asn Met Pro Glu Thr Leu Pro Asn Asn Ser Cys Tyr  
125 130 135

Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly Asp Glu Leu Gln Leu  
140 145 150

Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu Asp Gly Asp Val  
155 160 165

30 Thr Phe Phe Gly Ala Leu Lys Leu Leu  
170

<210> 6  
<211> 171  
35 <212> PRT  
<213> *Homo sapiens*  
<220>

<221> domain  
<222> 35..205  
<223> sequence of mature form of LT- $\alpha$   
<400> 6

5 Leu Pro Gly Val Gly Leu Thr Pro Ser Ala Ala Gln Thr Ala Arg  
5 10 15  
Gln His Pro Lys Met His Leu Ala His Ser Thr Leu Lys Pro Ala  
20 25 30  
Ala His Leu Ile Gly Asp Pro Ser Lys Gln Asn Ser Leu Leu Trp  
35 40 45  
10 Arg Ala Asn Thr Asp Arg Ala Phe Leu Gln Asp Gly Phe Ser Leu  
50 55 60  
Ser Asn Asn Ser Leu Leu Val Pro Thr Ser Gly Ile Tyr Phe Val  
65 70 75  
15 Tyr Ser Gln Val Val Phe Ser Gly Lys Ala Tyr Ser Pro Lys Ala  
80 85 90  
Thr Ser Ser Pro Leu Tyr Leu Ala His Glu Val Gln Leu Phe Ser  
95 100 105  
Ser Gln Tyr Pro Phe His Val Pro Leu Leu Ser Ser Gln Lys Met  
110 115 120  
20 Val Tyr Pro Gly Leu Gln Glu Pro Trp Leu His Ser Met Tyr His  
125 130 135  
Gly Ala Ala Phe Gln Leu Thr Gln Gly Asp Gln Leu Ser Thr His  
140 145 150  
25 Thr Asp Gly Ile Pro His Leu Val Leu Ser Pro Ser Thr Val Phe  
155 160 165  
Phe Gly Ala Phe Ala Leu  
170

30 <210> 7  
<211> 157  
<212> PRT  
<213> *Homo sapiens*  
<220>  
35 <221> domain  
<222> 77..233  
<223> sequence of mature form of TNF- $\alpha$

	<400>	7		
	Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His			
	5	10	15	
	Val Val Ala Asn Pro Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn			
5	20	25	30	
	Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly Val Glu Leu Arg Asp			
	35	40	45	
	Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Tyr Ser			
	50	55	60	
10	Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu			
	65	70	75	
	Leu Thr His Thr Ile Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys			
	80	85	90	
	Val Asn Leu Leu Ser Ala Ile Lys Ser Pro Cys Gln Arg Glu Thr			
15	95	100	105	
	Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu			
	110	115	120	
	Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu			
	125	130	135	
20	Ile Asn Arg Pro Asp Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val			
	140	145	150	
	Tyr Phe Gly Ile Ile Ala Leu			
	155			
25	<210>	8		
	<211>	152		
	<212>	PRT		
	<213>	<i>Homo sapiens</i>		
	<220>			
30	<221>	domain		
	<222>	130..281		
	<223>	sequence of mature form of FasL		
	<400>	8		
	Gln Ile Gly His Pro Ser Pro Pro Glu Lys Lys Glu Leu Arg			
	35	5	10	15
	Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro			
	20	25	30	

Leu Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val  
 35 40 45  
 Lys Tyr Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr  
 50 55 60  
 5 Phe Val Tyr Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn  
 65 70 75  
 Leu Pro Leu Ser His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro  
 80 85 90  
 Gln Asp Leu Val Met Met Glu Gly Lys Met Met Ser Tyr Cys Thr  
 10 95 100 105  
 Thr Gly Gln Met Trp Ala Arg Ser Ser Tyr Leu Gly Ala Val Phe  
 110 115 120  
 Asn Leu Thr Ser Ala Asp His Leu Tyr Val Asn Val Ser Glu Leu  
 125 130 135  
 15 Ser Leu Val Asn Phe Glu Glu Ser Gln Thr Phe Phe Gly Leu Tyr  
 140 145 150

Lys Leu

20 <210> 9  
 <211> 158  
 <212> PRT  
 <213> *Homo sapiens*  
 <220>  
 25 <221> domain  
 <222> 83..240  
 <223> sequence of mature form of LIGHT  
 <400> 9  
 Leu Ile Gln Glu Arg Arg Ser His Glu Val Asn Pro Ala Ala His  
 30 5 10 15  
 Leu Thr Gly Ala Asn Ser Ser Leu Thr Gly Ser Gly Gly Pro Leu  
 20 25 30  
 Leu Trp Glu Thr Gln Leu Gly Leu Ala Phe Leu Arg Gly Leu Ser  
 35 40 45  
 35 Tyr His Asp Gly Ala Leu Val Val Thr Lys Ala Gly Tyr Tyr Tyr  
 50 55 60  
 Ile Tyr Ser Lys Val Gln Leu Gly Gly Val Gly Cys Pro Leu Gly  
 65 70 75

Leu Ala Ser Thr Ile Thr His Gly Leu Tyr Lys Arg Thr Pro Arg  
80 85 90

Tyr Pro Glu Glu Leu Glu Leu Leu Val Ser Gln Gln Ser Pro Cys  
95 100 105

5 Gly Arg Ala Thr Ser Ser Ser Arg Val Trp Trp Asp Ser Ser Phe

110 115 120

Leu Gly Gly Val Val His Leu Glu Ala Gly Glu Glu Val Val Val  
125 130 135

Arg Val Leu Asp Glu Arg Leu Val Arg Leu Arg Asp Gly Thr Arg  
140 145 150

10 Ser Tyr Phe Gly Ala Phe Met Val  
155

<210> 10

15 <211> 7

<212> PRT

<213> *Homo sapiens*

<220>

20 <221> domain

<222> 112..118

<223> THANK terminal sequence

<400> 10

Leu Lys Ile Phe Glu Pro Pro

5

25

<210> 11

<211> 26

<212> DNA

<213> artificial sequence

30

<220>

<221> primer\_bind

<223> PCR primer used for amplifying the cDNA encoding  
the extracellular domain of THANK

<400> 11

35 gcgggatccc agcctccggg cagagc

26

<210> 12

<211> 26  
<212> DNA  
<213> artificial sequence  
<220>  
5 <221> primer\_bind  
<223> PCR primer used for amplifying the cDNA encoding  
the extracellular domain of THANK  
<400> 12

gcgtctagat cacagcactt tcaatgc

27

10 <210> 13  
<211> 5  
<212> PRT  
<213> *Homo sapiens*  
15 <220>  
<221> domain  
<222> 134..138  
<223> THANK terminal sequence  
<400> 13

20 Ala Val Gln Gly Pro

5

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/02751

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/19

US CL : 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2; 530/351, 388.22

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Sequence Databases, MPSRCH

SEQ ID NOS: 1-5

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/55621 A1 (REGENERON PHARMACEUTICALS, INC.) 10 December 1998 (10.12.98), see entire document, especially claims 13-15, and page 10, lines 19-24.	1-6
X	WO 98/27114 A2 (SCHERING CORPORATION) 25 June 1998 (25.06.98), see entire document, especially claims 1, 2 and 5, and page 7, line 26 to page 8, line 5, and page 28, lines 9-19, and page 37, line 15 to page 41, line 23, and page 40, lines 16-25.	1-6
X	WO 98/18921 A1 (HUMAN GENOME SCIENCES) 7 May 1998 (07.05.98), see claims 19 and 20, and page 11, lines 3-14, page 13, lines 3-13, page 48, line 14 to page 57, line 28.	1-6

 Further documents are listed in the continuation of Box C. See patent family annex.

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

26 APRIL 2000

Date of mailing of the international search report

19 JUN 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EILEEN B. O'HARA

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/02751

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 869 180 A1 (SMITHKLINE BEECHAM CORPORATION) 07 October 1998 (07.10.98), see claims 12-14 and page 12, lines 24-28 and 31-52, and page 14, line 12 to page 15, line 17.	1-6

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US00/02751**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/02751

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-3, drawn to a method of treating cells or individuals comprising administration of a THANK inhibitor.

Group II, claim(s) 4-6, drawn to a method of treating cells or individuals comprising administration of THANK protein. The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Pursuant to 37 C.F.R. § 1.475(d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the method reciting the first product, an inhibitor of THANK protein. Further pursuant to 37 C.F.R. § 1.475(d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.